Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-11-12
2009-08-04
Zeman, Robert A (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S014800, C530S300000, C530S324000, C530S326000, C530S327000
Reexamination Certificate
active
07569542
ABSTRACT:
The present invention is based on the discovery of a composition that provides targeted anti-microbial effect. Specifically the composition contains a targeting moiety which recognizes a target microbial organism and an anti-microbial peptide moiety which has anti-microbial activity. In addition, the present invention provides methods of treating a microbial infection, e.g., on mucosal surfaces by using the compositions provided by the present invention.
REFERENCES:
patent: 4671958 (1987-06-01), Rodwell
patent: 5057313 (1991-10-01), Shih et al.
patent: 5332567 (1994-07-01), Goldenberg
patent: 5645835 (1997-07-01), Fell, Jr. et al.
patent: 5646119 (1997-07-01), Oppenheim et al.
patent: 5672351 (1997-09-01), Chikindas et al.
patent: 5726293 (1998-03-01), Seed
patent: 5851527 (1998-12-01), Hansen
patent: 5910573 (1999-06-01), Pluckthun et al.
patent: 5981726 (1999-11-01), Pastan
patent: 6183744 (2001-02-01), Goldenberg
patent: 6197299 (2001-03-01), Dohlsten et al.
patent: 6492328 (2002-12-01), Lehrer et al.
patent: 2004/0052814 (2004-03-01), Shi et al.
patent: WO 99/58141 (1999-11-01), None
patent: WO 02/22686 (2002-03-01), None
patent: WO 94/09817 (1994-05-01), None
patent: WO 00/11037 (2000-03-01), None
patent: WO 02/15931 (2002-02-01), None
patent: WO 02/102975 (2002-12-01), None
Helmerhorst, E.J. et al., “Synthetic histatin analogues with broad-spectrum antimicrobial activity,” Biochem. J., vol. 326, 1997, pp. 39-45, XP002087342.
Tamamura, H. et al., “Synthesis of Protegrin-Related Peptides and Their Antibacterial and Anti-human Immunodeficiency Virus Activity,” Chem. Pharm. Bull., vol. 43, No. 5, 1995, pp. 853-858, XP000892198.
Database Biosis Biosciences Information Service, Philiadlephia, PA, US 2001, XP007901737, Yashin, B. et al., “Susceptibility ofChlamydia trachomatis serovarsL2, D, and E to G-10 novispirin.”
Marshall, S.A. et al., Spectrum and Antimicrobial Activity of Alexomycin (PNU-82, 127), a Peptide Compound Projected for Use in Animal Health, Diagn. Microbiol. Infect. Dis., vol. 33, 1999, pp. 181-186, XP002924752.
Sue M. Travis, et al., Bactericidal Activity of Mammalian Cathelicidin-Derived Peptides, Infection and Immunity, vol. 68 No. 5:2748-2755, American Society for Microbiology, May 2000 (United States).
Jens-M. Schroder, Commentary: Epithelial Peptide Anti-Biotics, Biochemical Pharmacology, vol. 57, pp. 121-134, 1999, Elsevier Science.
Manuel L. Penichet et al., Antibody-Cytokine Fusion Proteins For the Therapy of Cancer, Journal of Immunological Methods, vol. 248:91-1001 (2000), Elsevier Science B.V.
Peng Li et al., An Antimicrobial Peptide Gene Found in the Male Reproductive System Of Rats, Science vol. 291-1783-1785.
Sherie L. Morrison et al., Chimeric Human Antibody Molecules: Mouse Antigen-Binding Domains with Human Constant Region Domains, Proceedings of the National Academy Of Sciences U.S.A. vol. 81:6851-6855 (1984).
Kenneth T. Miyasaki et al., β-Sheet Antibiotic Peptides As Potential Dental Therapeutics, International Journal of Antimicrobial Agents, vol. 9:269-280 (1988), Elsevier Science, B.V.
Andrea Giacometti et al., “Antimicrobial Activity Of Polycationic Peptides,” vol. 20:1265-1273 (1999), Elsevier Science, Inc.
Kate Fortney et al.,Haemophilus ducreyiIs Susceptible to Protegrin, Antimicrobia Agents and Chemotherapy, vol. 42:2690-2693 (1998).
Database Dialog No. BG195051081. Ncolas, P., “Peptide as Weapons Against Microorganisms in the Chemical Defense System of Vertebrates.” Annual Review of Microbiology, vol. 49, pp. 277-304 (1995).
European Search Report for European Patent Application No. EP 02752402.4-2406, dated Sep. 9, 2005 (4 pages).
International Search Report for PCT/US02/22695 mailed Jan. 2, 2003 (4 pages).
European Examination Report mailed on Feb. 21, 2007, for EP Application No. EP 02752402.4 filed on Jul. 17, 2002,6 pages.
European Examination Report mailed on May 16, 2008, for EP Application No. 02752402.4 filed on Jul. 17, 2002, 7 pages.
Restriction Requirement mailed on Feb. 10, 2004, for U.S. Appl. No. 09/910,358, filed Jul. 19, 2001, 5 pages.
Notice of Abandonment and Interview Summary mailed on Sep. 17, 2004, for U.S. Appl. No. 09/910,358, filed Jul. 19, 2001, 3 pages.
Restriction Requirement mailed on Nov. 1, 2005, for U.S. Appl. No. 10/077,624, filed Feb. 14, 2002, 8 pages.
Office Action mailed on Jun. 6, 2006, for U.S. Appl. No. 10/077,624, filed Feb. 14, 2002, 11 pages.
Office Communication mailed on Mar. 20, 2007, for U.S. Appl. No. 10/077,624, filed Feb. 14, 2002, 3 pages.
Office Communication and Notice to Comply mailed on Oct. 31, 2007, for U.S. Appl. No. 10/077,624, filed Feb. 14, 2002, 17 pages.
Anderson Maxwell H.
Eckert Randal
Qi Fengxia
Shi Wenyuan
The Regents of the University of California
Townsend and Townsend / and Crew LLP
Zeman Robert A
LandOfFree
Anti-microbial targeting chimeric pharmaceutical does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-microbial targeting chimeric pharmaceutical, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-microbial targeting chimeric pharmaceutical will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4139338